Spain Diabetes Drugs Market Analysis Report [2022-30]

Spain Diabetes Drugs Market Analysis

$ 3999

The Spain diabetes drugs market size was valued at $1.19 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 5.1% from 2022 to 2030 and will reach $1.77 Bn in 2030. The market is segmented by drug type, application, and distribution channel. The Spain diabetes drug market will grow as the Spanish government has implemented several initiatives to improve diabetes care, including investing in diabetes education programs and supporting research into new treatments. The key market players are Almirall (ESP), Esteve (ESP), Laboratorios Rovi (ESP), Cinfa Biotech (ESP), Boehringer Ingelheim, and others.

ID: IN10ESPH009 CATEGORY: Pharmaceuticals GEOGRAPHY: Spain AUTHOR: Chandani Patel

Buy Now

Spain Diabetes Drugs Market Executive Summary

The Spain diabetes drugs market size was valued at $1.19 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 5.1% from 2022 to 2030 and will reach $1.77 Bn in 2030. Spain has a mixed economy with a strong focus on the service sector, including healthcare. In 2020, Spain had a gross domestic product (GDP) of approximately 1.2 trillion USD, making it the 13th largest economy in the world. Spain has a universal healthcare system, which is largely funded by the government. In 2019, total healthcare spending in Spain was approximately 10.2% of the country's GDP, which is above the average for European Union countries.

The Spanish healthcare system is financed through a combination of taxes and social security contributions. The system is decentralized, with responsibility for healthcare provision shared between the central government and the autonomous regions. The central government sets national health policies, while the regional governments are responsible for managing healthcare services within their territories.

Spain is one of the countries with a high prevalence of diabetes. According to the International Diabetes Federation, in 2021, there were an estimated 3.7 Mn people living with diabetes in Spain, which represents approximately 8% of the adult population. The incidence of diabetes in Spain is expected to increase in the coming years, driven by factors such as aging population, sedentary lifestyle, and unhealthy diets. The diabetes market in Spain is significant and growing, with a range of medications and devices available to manage the disease. The market includes products such as insulin, oral hypoglycemic agents, GLP-1 receptor agonists, and devices such as glucose monitoring systems and insulin pumps. The Spanish government has taken steps to improve diabetes care in the country, including investing in diabetes education programs and supporting research into new treatments.

The diabetes market in Spain is expected to continue to grow in the coming years, driven by factors such as the aging population and increasing awareness of the disease. However, manufacturers will need to navigate the challenges posed by budget constraints and increasing competition to succeed in the market.

spain diabetes drugs market

Market Dynamics

Market Growth Drivers Analysis

Increasing prevalence of diabetes: The prevalence of diabetes in Spain is high and continues to grow. According to the International Diabetes Federation, the number of people with diabetes in Spain is expected to reach 4.4 Mn by 2045.
Growing demand for diabetes treatments: The increasing prevalence of diabetes has led to a growing demand for diabetes treatments, including medications and devices.
Government initiatives to improve diabetes care: The Spanish government has implemented several initiatives to improve diabetes care, including investing in diabetes education programs and supporting research into new treatments.
Advancements in diabetes treatment technologies: Advancements in diabetes treatment technologies, including glucose monitoring systems and insulin pumps, are driving growth in the market.

Market Restraints

Budgetary constraints: Like many countries, Spain faces budgetary constraints in its healthcare system, which have led to restrictions on the use of certain diabetes medications and devices.
Increasing use of generic drugs: The increasing use of generic drugs has put pressure on prices and profit margins for manufacturers.
Reimbursement challenges: Reimbursement challenges, including delays in reimbursement and restrictions on the use of certain medications, have also impacted the market.

Competitive Landscape

Key Players

Almirall (ESP)
Esteve (ESP)
Laboratorios Rovi (ESP)
Cinfa Biotech (ESP)
Boehringer Ingelheim
Sanofi
Boehringer Ingelheim
Eli Lilly and Company
AstraZeneca
Johnson & Johnson
Bayer Pharmaceuticals
Novo Nordisk
Merck
Novartis
GlaxoSmithKline

Notable deals

In 2021, one notable transaction in the Spanish diabetes drugs market was the acquisition of Biomar Microbial Technologies, a Spanish biotechnology company focused on developing treatments for metabolic diseases, including diabetes, by the multinational healthcare company Novo Nordisk. This acquisition is part of Novo Nordisk's ongoing efforts to expand its portfolio of treatments for diabetes and related metabolic disorders.

Healthcare Policies and Regulatory Landscape

Policy changes and Reimbursement scenario

In Spain, diabetes drugs are regulated by the Spanish Agency of Medicines and Medical Devices (AEMPS), which is responsible for ensuring that all medications marketed in the country are safe, effective, and of high quality. The AEMPS requires that all diabetes drugs undergo rigorous clinical trials to demonstrate their safety and efficacy before they can be approved for use. Once approved, the AEMPS continues to monitor these drugs to ensure that they remain safe and effective for patients. In addition, the AEMPS also sets guidelines for the prescription, dispensation, and use of diabetes drugs. These guidelines help to ensure that diabetes medications are used appropriately and in accordance with best practices for diabetes care.

One important aspect of diabetes drug regulation in Spain is the requirement for pharmaceutical companies to provide information to patients and healthcare providers about the risks and benefits of these drugs. This information is typically provided in the form of package inserts or patient information leaflets, which outline important safety information and usage guidelines for each medication. The AEMPS plays a critical role in regulating the diabetes drugs market in Spain, helping to ensure that patients have access to safe, effective, and high-quality medications for the treatment of diabetes.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Diabetes Drugs Market Segmentation

By Drug Type (Revenue, USD Bn):

The drug types considered, in this report include Injectable Drugs and Oral Drugs. Injectable drugs are further classified into insulin-based and non-insulin-based injectables. Oral drugs are further classified into various classes as per their mechanism of action as mentioned below :

Injectable Drugs
- Insulin Based Injectables
- Non-insulin Based Injectables
  - Exenatide (Byetta)
  - Dulaglutide (Trulicity)
  - Semaglutide (Ozempic, Wegovy)
  - Liraglutide (`Saxenda, Victoza)
  - Lixisenatide (Adlyxin)
  - Pramlintide (Symlin)
  - Tirzepatide (Mounjaro)
  - Albiglutide (Tanzeum)
Oral Drugs
- Biguanides - Metformin (Glucophage and Glucophase XR)
- Sulfonylureas - Glimepiride (Amaryl), Glyburide (DiaBeta), Glipizide (Glucotrol), Gliclazide (Diamicron), Chlorpropamide (Diabinese)
- Meglitinides and D-Phenylalanine Derivatives - Repaglinide (Prandin), Nateglinide (Starlix)
- Thiazolidinediones (TZDs) - Rosiglitazone (Avandia), Pioglitazone (Actos)
- Dipeptidyl peptidase-IV (DPP-4) inhibitors - Sitagliptin (Januvia), Saxagliptin (Onglyza), Linagliptin (Tradjenta), and Alogliptin (Nesina and Vipidia), Teneligliptin (Tenelia), Vildagliptin (Galvus)
- Alpha-glucosidase Inhibitors - Acarbose (Precose), Miglitol (Glyset), Voglibose (Voglib)
- Sodium-glucose co-transporter-2 (SGLT2) inhibitors - Canagliflozin (Invokana), Dapagliflozin (Farxiga), Empagliflozin (Jardiance), Ertugliflozin (Stelgatro)
- Dopamine D2 agonist – Bromocriptine (Parlodel and Cycloset)
- Glucagon like peptide 1 (GLP-1) receptor agonists - Semaglutide (Rybelsus)
- Bile Acid Sequestrants (BASs) - Colesevelam (Welchol)
- Others (Fixed Dose Combination Drugs)

By Application (Revenue, USD Bn):

Based on application, the market is segmented into Type 1 and Type 2. The 2 types of diabetes drugs are segmented and dominate the market. The Type 2 diabetes segment accounts for the largest sales of the worldwide market a few different kinds. The excessive prevalence of type 2 because of sedentary lifestyles and obesity in all age groups is attributed to the current situation. Around 10% of all diabetes cases are type 1, and approximately 90% of all cases of diabetes in UK are type 2. Hence, it is estimated to the diabetes drugs market will grow across the globe during the forecast period.

Type 1 diabetes (due to β-cell destruction, usually leading to absolute insulin deficiency)
Type 2 diabetes (due to a progressive insulin secretory defect on the background of insulin resistance)
Other diabetes types

By Distribution Channel (Revenue, USD Bn):

Based on distribution channels, the market is classified into hospital pharmacies, rental pharmacies, and online pharmacies. The hospital pharmacies captured the highest market share, owing to the availability of trained & qualified personnel and favorable reimbursement structure. Online pharmacies are estimated to register the highest CAGR in the forecast period, it is attributed to the technological adaptation and acceptance of online pharmacies. Retail pharmacies showed a moderate market share improvement in the healthcare facilities in developing countries is anticipated to propel the popularity of retail pharmacies during the forecast period.

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

Insights10 will provide you with the reports within 10 key parameters which are:

Market Overview
Market Growth Drivers & Restraints
Epidemiology of Disease Type
Market Segmentation
Market Share
Competitive Landscape
Key Company Profiles
Healthcare Policies & Regulatory Framework
Reimbursement Scenario
Factors Driving Future Growth

Based on our many years of experience, we believe that these are the parameters that are critical to decision-making for business stakeholders. Our focused approach to developing reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.

Stage I: Market Data Collection

Primary Interviews: We have developed a network of experts, freelancers, and researchers across countries through which we engage with local experts to gather key data points and assumptions about each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.

Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain a high level of accuracy and consistency. The market data is analyzed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, and market share as well as a segment-level analysis of the specific market. Our report includes precise, to-the-point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.

Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:

Stage II: Market Data Analysis and Statistical Model

Market Trends: We generally look at macro parameters and micro indicators. The macro parameters include changes in government policies, demand and supply of the market, government intervention programs, and major market share. The micro indicators are GDP growth, market size, market volume, etc. We also understand nuances specific to each country like the US, Canada, India, Germany, etc., and have worked across 60+ countries and hence not only understand global trends but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.

Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. starting with the large overall market and segmenting different areas and the bottom-up approach i.e. starting with population and epidemiology and rolling up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.

The top-down approach is mainly used for new product forecasting and the bottom-up approach is used for demand estimation of any product for different countries summed up to form the total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.

The study on the market covers the analysis of the leading geographies such as Asia-Pacific, Africa, Europe, Middle East, North America, and Latin America for the period of 2022 to 2030. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape, and policy and regulatory scenario, and the quantitative analysis covers different market estimates and forecasts.

Data Triangulation & Validation:

Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases, and company-level averages, etc.

We make sure to finalize the numbers in alignment with the market research. Firstly, our internal experts ensure thorough validation and checking to ensure accurate and precise analysis and then validation is also done using a multiple-data analysis model. Two-level validation is done and entails the finalization of the report scope and the way of representation pattern.

Stage III: Interpretation and Presentation

Analysis & Interpretation: The information gathered is then analyzed and synthesized. The second series of interviews are done if necessary to check and validate. The future opportunities are analyzed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results is then, interpreted by considering the following parameters: (a partial list)

Establishing market drivers and trends
Analyzing the regulatory landscape to understand future growth
Market Segment based analysis to obtain revenue/volume
Analyzing current needs and determining penetration to estimate the market

Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to oﬀer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and their impact on the different segments within the market.

Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.

Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current, and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumption.

The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.